RCUS - After Disappointing Bladder Cancer Data Gilead Announces Encouraging Data From Gastric Colorectal Cancer Studies | Benzinga

On Saturday, Gilead Sciences Inc (NASDAQ:GILD) and Arcus Biosciences Inc (NYSE:RCUS) released longer-term efficacy and safety results from Arm A1 of the Phase 2 EDGE-Gastric study.

The updated data show consistent objective response rate (ORR) and provide mature progression-free survival (PFS) in patients with a locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma (upper GI cancers).

Related: Gilead’s Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder Cancer.

The ongoing, multi-arm, global Phase 2 EDGE-Gastric study is evaluating the safety and efficacy of various combinations of the Fc-silent anti-TIGIT antibody domvanalimab plus the anti-PD-1 monoclonal antibody zimberelimab and chemotherapy in this patient population.

At the data cutoff (March 12, 2024), safety ...

Full story available on Benzinga.com